

Takayuki Yoshimoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3758689/publications.pdf>

Version: 2024-02-01

68
papers

3,962
citations

117625

34
h-index

118850

62
g-index

70
all docs

70
docs citations

70
times ranked

4856
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Expression of Specific mRNA Transcripts after Single- or Re-Irradiation in Mouse Testes. <i>Genes</i> , 2022, 13, 151.	2.4	3
2	A novel coculture system for assessing respiratory sensitizing potential by IL-4 in T cells. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2022, , .	1.5	1
3	Rap1 prevents colitogenic Th17 cell expansion and facilitates Treg cell differentiation and distal TCR signaling. <i>Communications Biology</i> , 2022, 5, 206.	4.4	5
4	Microbial Antigen-Presenting Extracellular Vesicles Derived from Genetically Modified Tumor Cells Promote Antitumor Activity of Dendritic Cells. <i>Pharmaceutics</i> , 2021, 13, 57.	4.5	9
5	IL-23p19 and CD5 antigen-like form a possible novel heterodimeric cytokine and contribute to experimental autoimmune encephalomyelitis development. <i>Scientific Reports</i> , 2021, 11, 5266.	3.3	8
6	Interleukin-1 β in peripheral monocytes is associated with seizure frequency in pediatric drug-resistant epilepsy. <i>Journal of Neuroimmunology</i> , 2021, 352, 577475.	2.3	15
7	Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 403.	0.8	5
8	A Chaperone-Like Role for EBI3 in Collaboration With Calnexin Under Inflammatory Conditions. <i>Frontiers in Immunology</i> , 2021, 12, 757669.	4.8	5
9	Adding collagen to adipose tissue transplant increases engraftment by promoting cell proliferation, neovascularisation and macrophage activity in a rat model. <i>International Wound Journal</i> , 2021, , .	2.9	1
10	EBV-induced gene 3 augments IL-23 β protein expression through a chaperone calnexin. <i>Journal of Clinical Investigation</i> , 2020, 130, 6124-6140.	8.2	5
11	Necroptosis of Intestinal Epithelial Cells Induces Type 3 Innate Lymphoid Cell-Dependent Lethal Ileitis. <i>IScience</i> , 2019, 15, 536-551.	4.1	21
12	Plasmacytoid dendritic cells protect against immune-mediated acute liver injury via IL-35. <i>Journal of Clinical Investigation</i> , 2019, 129, 3201-3213.	8.2	27
13	Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors. <i>Oncolmmunology</i> , 2018, 7, e1421892.	4.6	2
14	Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. <i>Cancer Research</i> , 2018, 78, 182-194.	0.9	25
15	Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 1363-1376.	5.4	68
16	Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. <i>Archives of Dermatological Research</i> , 2017, 309, 315-321.	1.9	24
17	Integrin β 3 enhances the suppressive effect of interferon γ on hematopoietic stem cells. <i>EMBO Journal</i> , 2017, 36, 2390-2403.	7.8	28
18	Prediction of Chemical Respiratory and Contact Sensitizers by OX40L Expression in Dendritic Cells Using a Novel 3D Coculture System. <i>Frontiers in Immunology</i> , 2017, 8, 929.	4.8	19

#	ARTICLE	IF	CITATIONS
19	Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family. <i>Frontiers in Immunology</i> , 2016, 7, 479.	4.8	107
20	Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis. <i>PLoS Pathogens</i> , 2016, 12, e1005507.	4.7	60
21	IL-17A-producing CD30 ⁺ V β 1 T cells drive inflammation-induced cancer progression. <i>Cancer Science</i> , 2016, 107, 1206-1214.	3.9	28
22	Potential clinical application of interleukin-27 as an antitumor agent. <i>Cancer Science</i> , 2015, 106, 1103-1110.	3.9	49
23	Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo. <i>Oncology Reports</i> , 2015, 33, 292-296.	2.6	13
24	Therapeutic potential of interleukin-27 against cancers in preclinical mouse models. <i>Oncoimmunology</i> , 2015, 4, e1042200.	4.6	4
25	Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1151.	4.3	17
26	Contribution of IL-12/IL-35 Common Subunit p35 to Maintaining the Testicular Immune Privilege. <i>PLoS ONE</i> , 2014, 9, e96120.	2.5	24
27	Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse. <i>Oncoimmunology</i> , 2014, 3, e28861.	4.6	11
28	Intratumoral CD4 ⁺ T Lymphodepletion Sensitizes Poorly Immunogenic Melanomas to Immunotherapy with an OX40 Agonist. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1884-1892.	0.7	11
29	Interleukin-27: Regulation of Immune Responses and Disease Development by a Pleiotropic Cytokine with Pro- and Anti-inflammatory Properties. , 2014, , 353-375.		0
30	IL-27 promotes nitric oxide production induced by LPS through STAT1, NF- κ B and MAPKs. <i>Immunobiology</i> , 2013, 218, 628-634.	1.9	30
31	Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib. <i>Cancer Science</i> , 2013, 104, 1146-1153.	3.9	37
32	IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner. <i>PLoS ONE</i> , 2013, 8, e76159.	2.5	29
33	Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-13.	3.3	132
34	Activation Levels of Natural Killer Cells and CD8 ⁺ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2012, 120, 3745-3745.	1.4	1
35	Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production. <i>European Journal of Immunology</i> , 2011, 41, 2828-2839.	2.9	36
36	Local expression of interleukin-27 ameliorates collagen-induced arthritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2289-2298.	6.7	74

#	ARTICLE	IF	CITATIONS
37	Notch signaling drives IL-22 secretion in CD4 ⁺ T cells by stimulating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5943-5948.	7.1	147
38	A Pivotal Role for Interleukin-27 in CD8 ⁺ T Cell Functions and Generation of Cytotoxic T Lymphocytes. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	51
39	Antitumor Activities of Interleukin-27 on Melanoma. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2010, 10, 41-46.	1.2	18
40	Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27. Clinical and Developmental Immunology, 2010, 2010, 1-9.	3.3	144
41	Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy, 2010, 2, 697-709.	2.0	14
42	Interleukin-27 Activates Natural Killer Cells and Suppresses NK-Resistant Head and Neck Squamous Cell Carcinoma through Inducing Antibody-Dependent Cellular Cytotoxicity. Cancer Research, 2009, 69, 2523-2530.	0.9	95
43	Interleukins and cancer immunotherapy. Immunotherapy, 2009, 1, 825-844.	2.0	26
44	TGF- β^2 is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochemical and Biophysical Research Communications, 2009, 386, 105-110.	2.1	68
45	Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Molecular Immunology, 2009, 46, 1654-1662.	2.2	47
46	Antiproliferative Activity of IL-27 on Melanoma. Journal of Immunology, 2008, 180, 6527-6535.	0.8	122
47	STAT3 Is Indispensable to IL-27-Mediated Cell Proliferation but Not to IL-27-Induced Th1 Differentiation and Suppression of Proinflammatory Cytokine Production. Journal of Immunology, 2008, 180, 2903-2911.	0.8	68
48	Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood, 2008, 111, 1903-1912.	1.4	78
49	IL-27 Suppresses Th2 Cell Development and Th2 Cytokines Production from Polarized Th2 Cells: A Novel Therapeutic Way for Th2-Mediated Allergic Inflammation. Journal of Immunology, 2007, 179, 4415-4423.	0.8	180
50	IL-23 Enhances Host Defense against Vaccinia Virus Infection Via a Mechanism Partly Involving IL-17. Journal of Immunology, 2007, 179, 3917-3925.	0.8	50
51	Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. Journal of Bone and Mineral Metabolism, 2007, 25, 277-285.	2.7	80
52	Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology, 2006, 211, 427-436.	1.9	58
53	IL-27 Suppresses CD28-Mediated IL-2 Production through Suppressor of Cytokine Signaling 3. Journal of Immunology, 2006, 176, 2773-2780.	0.8	132
54	Interleukin-23 and Interleukin-27 Exert Quite Different Antitumor and Vaccine Effects on Poorly Immunogenic Melanoma. Cancer Research, 2006, 66, 6395-6404.	0.9	135

#	ARTICLE	IF	CITATIONS
55	Antiangiogenic and Antitumor Activities of IL-27. <i>Journal of Immunology</i> , 2006, 176, 7317-7324.	0.8	161
56	IL-27 Induces Th1 Differentiation via p38 MAPK/T-bet- and Intercellular Adhesion Molecule-1/LFA-1/ERK1/2-Dependent Pathways. <i>Journal of Immunology</i> , 2006, 177, 7579-7587.	0.8	106
57	A Role for IL-27 in Early Regulation of Th1 Differentiation. <i>Journal of Immunology</i> , 2005, 175, 2191-2200.	0.8	170
58	Augmentation of Effector CD8+ T Cell Generation with Enhanced Granzyme B Expression by IL-27. <i>Journal of Immunology</i> , 2005, 175, 1686-1693.	0.8	162
59	No inhibition of IL-27 signaling by soluble gp130. <i>Biochemical and Biophysical Research Communications</i> , 2005, 326, 724-728.	2.1	58
60	An Indispensable Role for STAT1 in IL-27-Induced T-bet Expression but Not Proliferation of Naive CD4+ T Cells. <i>Journal of Immunology</i> , 2004, 173, 3871-3877.	0.8	196
61	Induction of IgG2a Class Switching in B Cells by IL-27. <i>Journal of Immunology</i> , 2004, 173, 2479-2485.	0.8	125
62	Adjuvant Activities of Novel Cytokines, Interleukin-23 (IL-23) and IL-27, for Induction of Hepatitis C Virus-Specific Cytotoxic T Lymphocytes in HLA-A*0201 Transgenic Mice. <i>Journal of Virology</i> , 2004, 78, 9093-9104.	3.4	76
63	Potent Antitumor Activity of Interleukin-27. <i>Cancer Research</i> , 2004, 64, 1152-1156.	0.9	225
64	Positive Modulation of IL-12 Signaling by Sphingosine Kinase 2 Associating with the IL-12 Receptor β 1 Cytoplasmic Region. <i>Journal of Immunology</i> , 2003, 171, 1352-1359.	0.8	66
65	A Critical Role of Fc Receptor-Mediated Antibody-Dependent Phagocytosis in the Host Resistance to Blood-Stage <i>Plasmodium berghei</i> XAT Infection. <i>Journal of Immunology</i> , 2001, 166, 6236-6241.	0.8	64
66	Gamma Interferon Production Is Critical for Protective Immunity to Infection with Blood-Stage <i>Plasmodium berghei</i> XAT but Neither NO Production nor NK Cell Activation Is Critical. <i>Infection and Immunity</i> , 1999, 67, 2349-2356.	2.2	76
67	Interleukin-12-Dependent Mechanisms in the Clearance of Blood-Stage Murine Malaria Parasite <i>Plasmodium berghei</i> XAT, an Attenuated Variant of <i>P. berghei</i> NK65. <i>Journal of Infectious Diseases</i> , 1998, 177, 1674-1681.	4.0	30
68	CD40 Ligand Rescues Inhibitor of Differentiation 3-Mediated G1Arrest Induced by Anti-IgM in WEHI-231 B Lymphoma Cells. <i>Journal of the Royal Society of Medicine</i> , 1993, 16, 2453-2461.	0.1	0